康莱特注射液联合吉西他滨顺铂方案治疗晚期非小细胞肺癌的临床疗效及对患者免疫功能的影响

Clinical effect and the influence on immune function of Kanglaite injection combined with gemcitabine and cisplatin in the treatment of advanced non-small cell lung cancer

目的探讨康莱特注射液联合吉西他滨与顺铂(GP)方案治疗晚期非小细胞肺癌(NSCLC)的疗效及对患者免疫功能的影响。方法选取2013年4月至2015年4月间广州市花都区人民医院收治的88例晚期NSCLC患者,按照数字随机表法将患者分为研究组和对照组,每组44例。研究组患者采用康莱特注射液联合GP方案治疗,对照组患者单纯采用GP方案治疗。对比两组患者临床疗效、癌性疼痛、生活质量和治疗前后患者外周血T淋巴细胞活性的变化。结果两组患者治疗的总有效率比较,差异无统计学意义(P>0.05)。研究组患者癌性疼痛的完全缓解率为45.5%,显著高于对照组的22.7%(P<0.05)。研究组患者治疗后社会关系、精神情况、心理情况、治疗情况分值均低于对照组及治疗前(P<0.05)。治疗前两组患者CD3^+、CD4^+和CD8^+细胞活性比较差异无统计学意义(P>0.05);治疗后,研究组患者CD3^+、CD4^+和CD8^+细胞活性显著高于对照组,差异有统计学意义(P<0.05)。结论康莱特联合GP方案可以有效改善晚期NSCLC患者的免疫功能和生活质量,临床效果较好。

Objective To investigate the clinical effect and the influence on immune function of Kanglaite injection combined with gemcitabine and cisplatin （GP） in the treatment of advanced non-small cell lung cancer. Methods The 88 patients with advanced non-small cell lung cancer treated in Huadu People＇s Hospital from April 2013 to April 2015 were selected and divided into study group and control group, with 44 cases in each group according to the number of random method. Patients in study group were treated with GP regimen combination of Kanglaite injection in the treatment. Patients in the control group were treated with GP regimen in the treatment. The clinical effect, cancer pain, quality of life of the two groups and changes of T lymphocyte activity in peripheral blood of patients before and after treatment were observed. Results The total effective rate of treatment in the two groups was not statistically significant （P 〉 0. 05 ）. The complete remission rate of cancer pain in in study group was 45.5% , significantly higher than that of the control group （ P 〈 0.05 ）. The social relationship, mental status, psychological status and treatment situation of the study group were lower than those in the control group （ P 〈 0.05 ）. The activity of CD8^＋ , CD4^ ＋ and CD3^ ＋ cells in the two groups were not statistically significant （ P 〉 0. 05 ） , and the activity of CD8^＋ , CD4^＋ and CD3^ ＋ cells in the study group was significantly higher than that in control group （ P 〈 0.05 ）. Conclusion Kanglaite injection combined with GP regimen can effectively improve the advanced non-small cell lung cancer patients＇ immune function and quality of life, and the clinical effect is good.